惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

G
Google Developers Blog
D
Docker
Stack Overflow Blog
Stack Overflow Blog
GbyAI
GbyAI
OSCHINA 社区最新新闻
OSCHINA 社区最新新闻
Google DeepMind News
Google DeepMind News
M
MIT News - Artificial intelligence
H
Help Net Security
T
Tailwind CSS Blog
Engineering at Meta
Engineering at Meta
L
LangChain Blog
MongoDB | Blog
MongoDB | Blog
腾
腾讯CDC
H
Hackread – Cybersecurity News, Data Breaches, AI and More
S
SegmentFault 最新的问题
博
博客园 - 司徒正美
C
Check Point Blog
B
Blog
Y
Y Combinator Blog
Microsoft Azure Blog
Microsoft Azure Blog
P
Proofpoint News Feed
F
Fortinet All Blogs
美
美团技术团队
D
DataBreaches.Net

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
Ozempic Sat Unused For Decades Because Invention Is Not E...
American Institute For Economic Research · 2026-06-26 · via All Articles on Seeking Alpha

Summary

  • Led by Ozempic and Wegovy, glucagon-like peptides (GLP-1s) have become a global phenomenon, with one in eight US adults currently taking one.
  • The story of Ozempic is one of failed entrepreneurship, but also of its eventual success.
  • Pfizer, judging from how the story has been told, did not recognize the value of the drug.
Blue Ozempic pens with yellow measuring tape on pink background. Concept of diabetes treatment, weight loss aid, and modern healthcare solutions.Yellow measuring tape around the injectors.

Alones Creative/iStock via Getty Images

By Per Bylund

Pfizer (PFE) knew GLP-1s worked in 1990 but didn’t see their potential. The 30-year detour shows entrepreneurship matters as much as raw invention.

Led by Ozempic and Wegovy, glucagon-like peptides (GLP-1s) have become a

此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。